16 August 2022 : Original article
Evaluation of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program in Comparison to Standard Allocation
Nelly Delali Eklou1BCDE, Bernd M. Jänigen2E, Przemyslaw Pisarski2E, Gerd Walz1E, Johanna Schneider1ABCDEF*DOI: 10.12659/AOT.936514
Ann Transplant 2022; 27:e936514
Table 2 Immunosuppressive therapy, acute rejections, and graft function.
| Parameter | ESPn=116 | ETKASn=111 | p-value |
|---|---|---|---|
| Induction therapy | |||
| Antithymocyte globulin, n (%) | 11 (9.5) | 22 (19.8) | * |
| Basiliximab, n (%) | 94 (81.0) | 72 (64.9) | * |
| Unknown, n (%) | 11 (9.5) | 17 (15.3) | 0.227 |
| Maintenance therapy | |||
| Tacrolimus, n (%) | 114 (98.3) | 107 (96.4) | 0.438 |
| Everolimus, n (%) | 0 (0.0) | 5 (4.5) | * |
| Ciclosporine, n (%) | 2 (1.7) | 4 (3.6) | 0.438 |
| Prednisone, n (%) | 106 (93.0) | 103 (92.8) | 1.000 |
| Mycophenolate, n (%) | 108 (93.1) | 101 (91.0) | 0.628 |
| Mycophenolate, full dose, n (%) | 97 (83.6) | 93 (83.8) | 1.000 |
| Mycophenolate, reduced dose, n (%) | 11 (9.5) | 8 (7.2) | 0.635 |
| Triple immunosuppressive therapy as maintenance therapy | 105 (96.3) | 102 (96.2) | 1.000 |
| Rejections, n (%) | 28 (24.1) | 26 (23.4) | 1.000 |
| Time of rejection (months) | 16.2±5.7 | 5.4±1.6 | 0.084 |
| DGF, n (%) | 18 (15.5) | 17 (15.3) | 1.000 |
| Graft loss, n (%) | 21 (18.1) | 9 (8.1) | * |
| Duration between transplantation and graft loss (months) | 29.3±7.1 | 5.4±4.0 | * |
| Graft loss within the first year, n (%) | 11 (9.5) | 8 (7.2) | 0.635 |
| Cause of graft loss | |||
| Primary nonfunction, n (%) | 5 (4.3) | 4 (3.6) | 1.000 |
| Rejection, n (%) | 3 (2.6) | 1 (0.9) | 0.622 |
| Infection, n (%) | 5 (4.3) | 2 (1.8) | 0.447 |
| Thromboembolic events, n (%) | 4 (3.4) | 1 (0.9) | 0.370 |
| Unknown, n (%) | 4 (3.4) | 1 (0.9) | 0.370 |
| Data are presented as mean±standard error of the mean (SEM) unless otherwise indicated. Note that the percentage of different rejections refers to the total number of rejections. ABMR – antibody-mediated rejection; DGF – delayed graft function; ESP – Eurotransplant Senior Program; ETKAS – Eurotransplant Kidney Allocation System. * | |||